The reversible effects of raloxifene on luteinizing hormone levels and ovarian morphology in mice

This publication has 30 references indexed in Scilit:

• Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
  New England Journal of Medicine, 1997
• Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
  American Journal of Obstetrics and Gynecology, 1997
• Toremifene in Postmenopausal Breast Cancer
  Drugs & Aging, 1997
• Second Cancers After Adjuvant Tamoxifen Therapy for Breast Cancer
  JNCI Journal of the National Cancer Institute, 1996
• A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
  Journal of Bone and Mineral Research, 1996
• Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats
  The FASEB Journal, 1996
• Clinical Uses of Antiestrogens
  Obstetrical & Gynecological Survey, 1996
• Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *
  JNCI Journal of the National Cancer Institute, 1994
• Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
  Journal of Clinical Investigation, 1994
• Changes in the ovary of the mouse following exposure to X-rays. Part I.—Irradiation at three weeks old
  Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character, 1927